Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs

6 February 2023

Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets

24 January 2023

Helsinn closes financing agreement with Oberland Capital

24 January 2023

Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer

17 January 2023

Helsinn closes financing agreement with Oberland Capital

17 January 2023

Sintetica establishes US entity

17 October 2022

COMUNICATO STAMPA – Waldo Mossi eletto Vicepresidente di Farma Industria Ticino per il triennio 2022-2025

28 September 2022

Comunicato Stampa “Farma Industria Ticino and Credit Suisse Award for best student”

15 September 2022

Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine)  in Australia, Asia and the Middle East*

5 September 2022

Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer

17 August 2022